Antiepileptic drug review: Part 1

Surgical Neurology

Volumn 49, Issue 4, 1998, Pages 449-452

  Winkler, Susan R ^a   Luer, Mark S ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALCOHOL; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; DEXTROPROPOXYPHENE; ERYTHROMYCIN; ETHOSUXIMIDE; FLUCONAZOLE; FLUOXETINE; ISONIAZID; MESUXIMIDE; NICOTINAMIDE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SALICYLIC ACID; VALPROATE SEMISODIUM; VALPROIC ACID; WARFARIN;

ANTICONVULSANT THERAPY; BLOOD DYSCRASIA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG INDICATION; DRUG MONITORING; GASTROINTESTINAL DISEASE; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; REVIEW; SEIZURE; THROMBOPHLEBITIS;

EID: 0032054321     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(97)00223-1     Document Type: Article

References (17)

1. 1. Kerr BM, Levy RH. Carbamazepine: carbamazepine epoxide. In: Levy RH, Mattson RH, Meldrum BS, Penry JK, Dreifuss FE, eds. Antiepileptic drugs, third edition. New York: Raven Press, Ltd. 1989:505-20.
2. 2. Levy RH, Kerr BM. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry 1988;49(Suppl):58-61.
3. 3. Riva R, Contin M, Albani F, et al. Free concentration of carbamazepine and carbamazepine 10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication. Clin Pharmacokinet 1985;10: 524-31.
4. 4. Robbins DK, Wedlund PJ, Buhn R, et al. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 1990;29:759-62.
5. 5. Bourgeois BFD. Primidone: biotransformation and mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, Penry JK, Dreifuss FE, eds. Antiepileptic drugs, third edition. New York: Raven Press, Ltd., 1989:401-12.
6. 6. Rust RS, Dodson WE. Phenobarbital: absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS, Penry JK, Dreifuss FE, eds. Antiepileptic drugs, third edition. New York: Raven Press, Ltd., 1989:293-304.
7. 7. Cacek AT. Reviews of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food. Ther Drug Monit 1986;8:166-71.
8. 8. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982; 32:570-2.
9. 9. Tozer TN, Winter WE. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring, third edition. Vancouver: Applied Therapeutics, Inc., 1992: 25-1-25-44.
10. 10. Bauer LA, Blouin RA. Phenytoin Michaelis-Menten pharmacokinetics in caucasian paediatric patients. Clin Pharmacokinet 1983;8:545-9.
11. 11. Cloyd JC, Gumnit RJ, McLain LW. Status epilepticus: the role of intravenous phenytoin. JAMA 1980;244: 1479-81.
12. 12. Donovan PJ, Cline D. Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med 1991;20:139-42.
13. 13. Wilder BJ. Pharmacokinetics of valproate and carbamazepine. J Clin Psychopharm 1992;12:64S.
14. 14. Cloyd JC, Brundage RC. Valproic Acid. In: Taylor WJ, Caviness MHD, eds. Clinical application of therapeutic monitoring. Irving: Abbott Laboratories, 1986:269-80.
15. 15. Hall K, Otten N, Johnson B, et al. A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol 1985;25:261-8.
16. 16. Nau H, Loscher W. Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia 1984;25(1 Suppl):S14-S22.
17. 17. Cloyd JC, Kriel RL, Fischer JH. Valproic acid pharmacokinetics in children. II. Discontinuation of concomitant antiepileptic drug therapy. Neurology 1985;35: 1623-7.